Aetna modified CPB 0845 for carfilzomib (Kyprolis), effective March 3, 2026. Here's what billing teams need to do.
Aetna, a CVS Health company, updated its carfilzomib (Kyprolis) coverage policy under CPB 0845 on March 3, 2026. This policy governs medical necessity for J9047 (injection, carfilzomib, 1 mg) across multiple myeloma and several adjacent plasma cell disorders. The change affects oncology billing teams, specialty infusion centers, and any practice administering carfilzomib under Aetna commercial plans — and the combination regimen criteria have real claim denial exposure if you're not billing the right partner drugs.
Quick Reference: Aetna CPB 0845 Carfilzomib Policy Change 2026
| Field | Detail |
|---|---|
| Payer | Aetna, a CVS Health company |
| Policy | Carfilzomib (Kyprolis) — CPB 0845 |
| Policy Code | CPB 0845 |
| Change Type | Modified |
| Effective Date | March 3, 2026 |
| Impact Level | High |
| Specialties Affected | Hematology/Oncology, Specialty Infusion, Hospital Outpatient |
| Key Action | Confirm your combination regimen and prior authorization documentation match the updated CPB 0845 criteria before submitting claims |
Aetna Carfilzomib Coverage Criteria and Medical Necessity Requirements 2026
The Aetna carfilzomib coverage policy under CPB 0845 is combination-regimen-specific. Medical necessity approval lives or dies on which drugs you're pairing with J9047.
Precertification is mandatory for all Aetna participating providers billing carfilzomib for multiple myeloma. Call (866) 752-7021 or fax (888) 267-3277 to initiate prior authorization. Use the Specialty Pharmacy Precertification forms from Aetna's provider portal.
Multiple Myeloma — Initial Approval Criteria
Aetna covers carfilzomib for multiple myeloma under seven distinct pathways. Each one turns on disease stage, transplant candidacy, and the specific combination regimen.
Transplant-eligible, first-line treatment requires one of two combinations:
| # | Covered Indication |
|---|---|
| 1 | Isatuximab-irfc (J9227), lenalidomide, and dexamethasone |
| 2 | Daratumumab (J9145), lenalidomide, and dexamethasone |
Single-agent use is covered after one or more prior lines of therapy. No combination partner required.
Relapsed/refractory disease with three or more prior lines — carfilzomib must be combined with bendamustine (J9033, J9034, J9036, or J9056) and dexamethasone.
Relapsed or progressive disease with t(11;14) translocation — carfilzomib pairs with venetoclax and dexamethasone. This is a genotype-gated pathway. Confirm molecular testing documentation is in the chart before submitting.
Relapsed, refractory, or progressive disease covers the broadest set of combinations:
| # | Covered Indication |
|---|---|
| 1 | Cyclophosphamide (J8530, J9071–J9076), thalidomide, and dexamethasone |
| 2 | Pomalidomide and dexamethasone |
| 3 | Pomalidomide, daratumumab (J9145), and dexamethasone |
| 4 | Daratumumab (J9145) and dexamethasone |
| 5 | Daratumumab and hyaluronidase-fihj (J9144) and dexamethasone |
| 6 | Isatuximab-irfc (J9227) and dexamethasone |
| 7 | Selinexor and dexamethasone |
| 8 | Dexamethasone alone |
Lenalidomide or cyclophosphamide-based regimens — carfilzomib combined with lenalidomide plus dexamethasone, or cyclophosphamide plus dexamethasone, covers a separate pathway without a relapse/refractory requirement.
Transplant-eligible maintenance — carfilzomib with lenalidomide is covered for maintenance therapy.
Beyond Multiple Myeloma
The coverage policy extends to three additional indications with their own criteria.
POEMS syndrome, plasma cell-related MIDD, and plasma cell-related MGRS — Aetna covers carfilzomib for all three without additional sub-criteria. The diagnosis alone qualifies.
Systemic light chain amyloidosis — two pathways apply. Carfilzomib as a single agent for relapsed/refractory non-cardiac disease, or carfilzomib combined with dexamethasone.
Waldenström macroglobulinemia/lymphoplasmacytic lymphoma — carfilzomib must be used in combination with rituximab (J9312, J9311, or biosimilars Q5115, Q5119, Q5123) and dexamethasone.
Continuation of Therapy
Aetna also defines continuation criteria. Reauthorization requires the member to be receiving carfilzomib for an indication listed in the initial approval criteria.
Aetna Carfilzomib Exclusions and Non-Covered Indications
Aetna considers all other indications for carfilzomib experimental, investigational, or unproven. The policy is explicit: if the indication isn't in the approved list, it doesn't qualify under this coverage policy.
This matters most for off-label use. Carfilzomib has a growing body of literature supporting use in other plasma cell disorders. Aetna isn't following all of that yet. If your oncologist is using carfilzomib for an indication outside POEMS, amyloidosis, Waldenström's, or multiple myeloma — expect a denial under CPB 0845 and plan your appeals strategy before you infuse.
The real risk area is the t(11;14)/venetoclax pathway. That pathway requires documented translocation status. If your chart doesn't have confirmed molecular testing, Aetna will treat it as unsupported and deny.
Coverage Indications at a Glance
| Indication | Status | Key Regimen/Criteria | Notes |
|---|---|---|---|
| Multiple myeloma — transplant eligible, 1st line | Covered | + isatuximab-irfc + lenalidomide + dex, OR + daratumumab + lenalidomide + dex | Prior auth required |
| Multiple myeloma — single agent | Covered | ≥1 prior line of therapy | Prior auth required |
| Multiple myeloma — relapsed/refractory, ≥3 prior lines | Covered | + bendamustine + dexamethasone | Prior auth required |
| Multiple myeloma — relapsed/progressive, t(11;14) | Covered | + venetoclax + dexamethasone | Molecular testing documentation required |
| Multiple myeloma — relapsed/refractory/progressive | Covered | Multiple combination options (see criteria) | Prior auth required |
| Multiple myeloma — lenalidomide or cyclophosphamide-based | Covered | + lenalidomide + dex, OR + cyclophosphamide + dex | Prior auth required |
| Multiple myeloma — transplant eligible, maintenance | Covered | + lenalidomide | Prior auth required |
| POEMS syndrome | Covered | Diagnosis alone qualifies | Prior auth required |
| Plasma cell-related MIDD | Covered | Diagnosis alone qualifies | Prior auth required |
| Plasma cell-related MGRS | Covered | Diagnosis alone qualifies | Prior auth required |
| Systemic light chain amyloidosis | Covered | Single agent (relapsed/refractory, non-cardiac) OR + dexamethasone | Prior auth required |
| Waldenström macroglobulinemia/lymphoplasmacytic lymphoma | Covered | + rituximab + dexamethasone | Prior auth required |
| All other indications | Not Covered | — | Considered experimental/investigational |
Aetna Carfilzomib Billing Guidelines and Action Items 2026
Carfilzomib billing under CPB 0845 has more moving parts than most oncology drug policies. The combination partner drugs each have their own HCPCS codes, and if you're submitting claims without the full regimen documented, you're building toward denials. Here's what to do now.
| # | Action Item |
|---|---|
| 1 | Audit your prior authorization workflow against the March 3, 2026 effective date. Every carfilzomib claim under an Aetna commercial plan requires precertification. Call (866) 752-7021 or fax (888) 267-3277. Make sure your authorization request documents the specific combination regimen — not just "carfilzomib for multiple myeloma." |
| 2 | Map your regimen to the correct HCPCS codes for all combination agents. Daratumumab has two HCPCS codes: J9145 (IV) and J9144 (subcutaneous with hyaluronidase-fihj). Bill the wrong one and you're misrepresenting the product administered. Isatuximab-irfc bills as J9227. Bendamustine has four active codes — J9033, J9034, J9036, and J9056 — depending on the product. |
| 3 | Confirm molecular testing documentation for the t(11;14)/venetoclax pathway. If your oncologist is using carfilzomib plus venetoclax for relapsed or progressive disease, the translocation must be confirmed in the medical record before you submit. Aetna will pull this in a prior auth review. Treat missing molecular test results as a claim denial waiting to happen. |
| 4 | Use the correct administration codes. The policy lists CPT codes 96413–96417 and 96409/96411 as related administration codes. Consult your coding resources to select the appropriate code based on the method and duration of infusion. |
| 5 | Update your charge capture for J9047 to prompt for combination agent documentation. The Aetna Kyprolis coverage policy is regimen-specific, not indication-specific. A charge capture that only captures the carfilzomib line leaves your billing team without the partner drug documentation they need to survive a prior auth review or an audit. Build in a hard stop for combination agent entry. |
| 6 | Verify ICD-10 diagnosis codes match the approved indication before submission. The policy includes 305 ICD-10-CM codes. The complete list is available in CPB 0845 on Aetna's provider portal. Do not rely on partial code ranges — pull the full list and map to your EHR before submitting claims under the updated policy. |
If you're managing a high volume of Aetna commercial carfilzomib claims and your regimen mix is complex, talk to your compliance officer before submitting under the updated policy. The criteria are specific enough that a wrong assumption about which pathway applies can produce large-scale denials.
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Carfilzomib Under CPB 0845
Covered HCPCS Codes (When Selection Criteria Are Met)
| Code | Type | Description |
|---|---|---|
| J9047 | HCPCS | Injection, carfilzomib, 1 mg |
| J1100 | HCPCS | Injection, dexamethasone sodium phosphate, 1 mg |
| J8530 | HCPCS | Cyclophosphamide, oral, 25 mg |
| J8540 | HCPCS | Dexamethasone, oral, 0.25 mg |
| J8541 | HCPCS | Dexamethasone (Hemady), oral, 0.25 mg |
| J9033 | HCPCS | Injection, bendamustine hydrochloride, 1 mg |
| J9034 | HCPCS | Injection, bendamustine HCl (Bendeka), 1 mg |
| J9035 | HCPCS | Injection, bevacizumab, 10 mg |
| J9036 | HCPCS | Injection, bendamustine hydrochloride (Belrapzo/bendamustine), 1 mg |
| J9046 | HCPCS | Injection, bortezomib (Dr. Reddy's), not therapeutically equivalent to J9041, 0.1 mg |
| J9048 | HCPCS | Injection, bortezomib (Fresenius Kabi), not therapeutically equivalent to J9041, 0.1 mg |
| J9049 | HCPCS | Injection, bortezomib (Hospira), not therapeutically equivalent to J9041, 0.1 mg |
| J9051 | HCPCS | Injection, bortezomib (Maia), not therapeutically equivalent to J9041, 0.1 mg |
| J9056 | HCPCS | Injection, bendamustine hydrochloride (Vivimusta), 1 mg |
| J9071 | HCPCS | Injection, cyclophosphamide (Auromedics), 5 mg |
| J9072 | HCPCS | Injection, cyclophosphamide (Frindovyx), 5 mg |
| J9073 | HCPCS | Injection, cyclophosphamide (Dr. Reddy's), 5 mg |
| J9074 | HCPCS | Injection, cyclophosphamide (Sandoz), 5 mg |
| J9075 | HCPCS | Injection, cyclophosphamide, not otherwise specified, 5 mg |
| J9076 | HCPCS | Injection, cyclophosphamide (Baxter), 5 mg |
| J9144 | HCPCS | Injection, daratumumab, 10 mg and hyaluronidase-fihj |
| J9145 | HCPCS | Injection, daratumumab, 10 mg |
| J9227 | HCPCS | Injection, isatuximab-irfc, 10 mg |
| J9311 | HCPCS | Injection, rituximab 10 mg and hyaluronidase |
| J9312 | HCPCS | Injection, rituximab, 10 mg |
| Q5115 | HCPCS | Injection, rituximab-abbs, biosimilar (Truxima), 10 mg |
| Q5119 | HCPCS | Injection, rituximab-pvvr, biosimilar (Ruxience), 10 mg |
| Q5123 | HCPCS | Injection, rituximab-arrx, biosimilar (Riabni), 10 mg |
CPT Administration Codes
| Code | Type | Description |
|---|---|---|
| 96365 | CPT | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
| 96366 | CPT | Intravenous infusion; each additional hour |
| 96367 | CPT | Intravenous infusion; additional sequential infusion, up to 1 hour |
| 96368 | CPT | Intravenous infusion; concurrent infusion |
| 96379 | CPT | Unlisted therapeutic, prophylactic, or diagnostic intravenous or intra-arterial injection or infusion |
| 96409 | CPT | Chemotherapy administration; intravenous, push technique, single or initial substance/drug |
| 96411 | CPT | Chemotherapy administration; intravenous, push technique, each additional substance/drug |
| 96413 | CPT | Chemotherapy administration, intravenous infusion technique; up to 1 hour |
| 96414 | CPT | Chemotherapy administration, intravenous infusion technique; each additional hour |
| 96415 | CPT | Chemotherapy administration, intravenous infusion technique; each additional hour |
| 96416 | CPT | Chemotherapy administration, intravenous infusion technique; initiation of prolonged chemotherapy infusion |
| 96417 | CPT | Chemotherapy administration, intravenous infusion technique; each additional sequential infusion |
ICD-10-CM Diagnosis Codes
The policy includes 305 ICD-10-CM codes. The complete list is available in CPB 0845 on Aetna's provider portal. Do not rely on partial code ranges — pull the full list and map to your EHR before submitting claims under the updated policy.
The truncated source data includes codes across a wide range of oncology diagnoses. Some of those codes are not obviously tied to carfilzomib's approved indications. Pulling only a partial list and assuming relevance creates real denial risk. Get the full code set from the policy document before you finalize your EHR mapping.
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.